Copyright © Inderes 2011 - present. All rights reserved.

Biohit

3.69 EUR

+1.93 %

4,892 following

BIOBV

NASDAQ Helsinki

Medical Equipment & Services

Health Care

+1.93 %
+19.03 %
+29.47 %
+33.70 %
+61.14 %
+64.00 %
+114.53 %
+85.43 %
-29.04 %

Biohit operates in the medical technology sector. The company develops and manufactures laboratory equipment, consumables and diagnostic analysis systems adapted for research, healthcare and industrial laboratories. In addition to its main business, it offers technical support, maintenance and training services within the aforementioned field of work. The largest operations are conducted in the Nordic market. The company has its headquarters in Helsinki.

Read more
Market cap
56.08M EUR
Turnover
86.54K EUR
P/E (adj.) (25e)
26.6
EV/EBIT (adj.) (25e)
19.72
P/B (25e)
3.89
EV/S (25e)
3.16
Dividend yield-% (25e)
0.94 %
Coverage
Recommendation
Reduce
Target price
3.70 EUR
Updated
13.11.2025
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 13.11.2025

Latest extensive report

Released: 15.01.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
11.2
2026

Annual report '25

3.6
2026

General meeting '26

5.8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
It’s great that this year marks 20 years since Gastropanel’s market entry, so it would be high time to make it big
12/8/2025, 3:11 PM
by Junkbondking
7
Certainly not news that would cause a positive earnings warning, but for the first time in a long time, hangover + Acetium in a newspaper article. So no idea how much sales there needs to be for the wholesaler to run out. Helsingin Sanomat – 10 Dec 25 Alkoholi | Krapulan torjumiseen...
12/10/2025, 2:49 PM
by elCobra
4
Here are Antti’s comments regarding the recent Gastropanel study. Biohit announced on Monday a new clinical study supporting the reliability of the GastroPanel test in ruling out the need for gastroscopy (stomach endoscopy). The news supports the company’s growth story and sales ...
12/9/2025, 6:14 AM
by Sijoittaja-alokas
4
It should also be emphasized that L-cysteine is released from Acetium at a controlled rate locally in the stomach, while from other products, cysteine is intended to be absorbed from the small intestine into the bloodstream.
yesterday
by Junkbondking
3
Of course, the patient’s symptoms, history, and risk factors influence the decision.
12/8/2025, 11:29 AM
by PaulKo
2
Very welcome news! However, as you noted, it probably doesn’t have much significance yet in terms of euros. In 2024, Biohit’s revenue from Finland was a total of 0.2 million euros.
yesterday
by PeterPan
1
At least according to that press release: “Up to 90% of gastroscopies can be avoided when the GastroPanel® result is normal.” And in the CEO’s own words (in the same release), the same claim: Biohit CEO Jussi Hahtela: “The results are very clear: when the GastroPanel® result is normal...
12/8/2025, 2:04 PM
by Balle Ramsted - pienehkö kasvusijoittaja nupullaan
1
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.